In this fifth update to the living guidelines on drugs for the treatment of COVID-19, the World Health Organization analyzed results of clinical trials that assessed the effects of casirivimab-imdevimab and corticosteroids in patients with severe and non-severe disease.
Chronic kidney disease increases the risk of cardiovascular events associated with type 2 diabetes. A clinical trial sought to discover if finerenone would help patients with both of these conditions.
Investigators report findings from the Dapagliflozin and Prevention of Adverse outcomes in CKD (DAPA-CKD) study.
This review examines the current guidance and issues related to lipid optimization of patients with peripheral arterial disease (PAD).
docosahexaenoic acid affected the risk for incident atrial fibrillation.
Researchers assessed the ability of antihypertensive drugs to cross the blood-brain barrier.
Investigators sought to assess the impact of treatment with SGLT2 inhibitors on risk of all-cause mortality, cardiovascular disease, or hospitalization for heart failure or chronic kidney disease in patients with type 2 diabetes.
Investigators conducted a study to assess the effects of moderate glycosuria on group
B Streptococcus .
The BBV152 vaccine, produced by Bharat Biotech International, was a whole-virion -propiolactone-inactivated SARS-CoV-2 vaccine formulated by Algel-alum or Algel-IMDG adjuvants.
Patients who are older and have systolic, diastolic, and renal dysfunction may benefit from peri-interventional preload reduction therapy before implantation of larger left atrial devices.
